Yuji Sato - Publications

Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II.

Journal: British journal of clinical pharmacology

Published: October 06, 2025

Combined treatment with mesenchymal stem cells and therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy: a phase 1/2 randomized trial.

Journal: Scientific reports

Published: July 11, 2024

Corrigendum to "On emerging enzyme replacement therapies for neuronopathic mucopolysaccharidosis II" [Molecular Genetics and Metabolism Volume 141, Issue 3 (2024) 108143].

Journal: Molecular genetics and metabolism

Published: February 10, 2024

On emerging enzyme replacement therapies for neuronopathic mucopolysaccharidosis II.

Journal: Molecular genetics and metabolism

Published: December 14, 2023

Efficacy and safety of GH treatment in Japanese children with short stature due to SHOX deficiency: a randomized phase 3 study.

Journal: Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology

Published: October 31, 2023

α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: October 10, 2023

Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan.

Journal: Orphanet journal of rare diseases

Published: August 20, 2023

Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme.

Journal: Molecular genetics and metabolism reports

Published: August 17, 2022

Treatment of Neuronopathic Mucopolysaccharidoses with Blood-Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis.

Journal: Pharmaceutics

Published: May 19, 2022

Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study.

Journal: Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society

Published: April 14, 2022

Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid.

Journal: Metabolic brain disease

Published: November 15, 2021

Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data.

Journal: International journal of molecular sciences

Published: August 25, 2021